filmov
tv
Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML
Показать описание
Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid leukemia.
0:03:40
0:07:03
0:04:03
0:01:39
0:02:02
0:04:07
0:04:18
0:07:53
0:03:20
0:03:02
0:04:49
0:03:20
0:02:27
0:02:01
0:03:14
0:03:45
0:02:49
0:06:47
0:03:46
0:17:34
0:01:25
0:04:15
0:02:32
0:02:57